BiomX (PHGE) Income from Continuing Operations (2018 - 2026)
BiomX (PHGE) posted Income from Continuing Operations of 19140000.0 for Q1 2026, down 204.49% sequentially from 18317000.0 in Q4 2025, and down 149.9% YoY from 38355117.74 in Q1 2025.
BiomX (PHGE) Income from Continuing Operations (2018 - 2026) Analysis & Trends
BiomX has reported Income from Continuing Operations for 9 years, with the latest figure at 19140000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 149.9% year-over-year to 19140000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 16026000.0 (down 194.83% YoY) and the FY2025 annual result came in at 4545000.0, down 162.85% from the prior year.
- Income from Continuing Operations fell to 19140000.0 in Q1 2026 per PHGE's latest filing, from 18317000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 18317000.0 in Q4 2025 and troughed at 19140000.0 in Q1 2026.
- A 5-year average of 2022000.0 and a median of 6386000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations surged 290.22% in 2024, then slumped 235.03% in 2025.
- Over 5 years, Income from Continuing Operations stood at 15375000.0 in 2022, then sank by 135.71% to 5491000.0 in 2023, then soared by 290.22% to 10445000.0 in 2024, then surged by 75.37% to 18317000.0 in 2025, then tumbled by 204.49% to 19140000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 19140000.0, 18317000.0, and 9166000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | BiomX | 351,774.34 | -816,225.66 | - | -19.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.14 Mn |
| Dec 31, 2025 | 18.32 Mn |
| Sep 30, 2025 | -9.17 Mn |
| Jun 30, 2025 | -6.04 Mn |
| Mar 31, 2025 | -7.66 Mn |
| Dec 31, 2024 | 10.45 Mn |
| Sep 30, 2024 | 9.64 Mn |
| Jun 30, 2024 | 4.47 Mn |
| Dec 31, 2023 | -5.49 Mn |
| Sep 30, 2023 | -7.91 Mn |
| Jun 30, 2023 | -6.41 Mn |
| Mar 31, 2023 | -6.36 Mn |
| Dec 31, 2022 | 15.38 Mn |
| Sep 30, 2022 | -6.78 Mn |
| Jun 30, 2022 | -7.48 Mn |
| Mar 31, 2022 | -8.17 Mn |
| Dec 31, 2021 | -10.46 Mn |
| Sep 30, 2021 | -10.03 Mn |
| Jun 30, 2021 | -7.34 Mn |
| Mar 31, 2021 | -8.40 Mn |